Progyny Inc

PGNY remains in a healthy Stage 2 uptrend with Parabola-driven acceleration along rising EMAs, but price is extended and in extreme overbought territory, making immediate entry unfavorable. We maintain a bullish medium-term bias while deferring execution, stalking pullbacks into the rising 9EMA/21EMA support zone for better risk/reward.

• ↑Q1 2026 revenue $328.5M, topping guidance $315–330M
• ↑Full-year revenue outlook lifted to $1.98–2.09B
• ↓Weak profitability conversion, margins below industry norms